Biodexa Pharmaceuticals AGM Postponed Due to Lack of Quorum, Critical Reverse Split Vote Delayed
BDRX is trading near its 52-week low of $2.86 (5.2% above the low).
Summary
Biodexa Pharmaceuticals Plc's Annual General Meeting was postponed due to a lack of quorum and has been re-scheduled for June 30. This meeting was set to vote on a highly significant 1-for-10,000 reverse stock split, as previously disclosed in a May 14 6-K filing. The inability to achieve a quorum for such a critical vote raises concerns about shareholder engagement and the company's ability to pass the proposed reverse split, which is likely essential for its continued listing or financial stability given its micro-cap status. Investors should watch the re-scheduled meeting on June 30 for further developments.
At the time of this announcement, BDRX was trading at $3.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3M. The 52-week trading range was $2.86 to $66.50. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.